NASDAQ · CPRX
Catalyst Pharmaceutical Inc.
$31.49 +$0.01 (+0.03%) 1D
Catalyst Pharmaceutical Inc.
Key Metrics
$3.85B
Market cap
17.41×
P/E · TTM
$7.97M
Revenue · TTM
$221.32M
Net income
EPS · TTM
$1.74
Dividend yield
—
Free cash flow
—
Beta · 1Y
0.66
EBITDA · TTM
—
Gross margin
—
Snapshot
Market cap$3.85B
Enterprise value—
Shares outstanding122.4M
52-wk range$19.05 – $32.56
Avg volume · 20D1.5M
Net cash
—
Book value / share$7.98
IndustryPharmaceutical Preparations
ExchangeNASDAQ
About Catalyst Pharmaceutical Inc.
IPO dateNov 8, 2006
Employees182
Catalyst Pharmaceuticals Inc is a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare and difficult to treat diseases.
Wolf Grade COMING SOON
—
The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.
Valuation
P/E17.41
P/S483.59
P/FCF—
EV/EBITDA—
EV/Sales—
Graham №$17.69
Profitability
Gross
—
Operating
162.4%
Net
2,777.3%
FCF
—
ROE / ROIC
25.4% · —
Financial Health
Current ratio7.10
Quick ratio6.84
Debt / equity—
Debt / EBITDA
—
Net cash
—
Working capital$807.99M
Cash Flow · TTM
Operating CF
—
Capex
—
Free cash flow
—
Buybacks
—
Dividends paid
—
Shareholder yield
—
Piotroski F-Score
0 / 9
Weak fundamentals · 0 of 9 signals passing
Altman Z-Score
18.7
Safe zone (> 2.99) · bankruptcy risk negligible
Graham Number vs Price
$17.69 vs $31.49
Trades 1.8× above classic defensive value — priced for growth
Fundamentals through 2026-03-31 · computed by TickerWolf from SEC filings